In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques.

Says Professor André Deelder, Head of the Department of Parasitology/Biomolecular Mass Spectrometry Unit, at the Center for Infectious Diseases in the Leiden University Medical School:
“Degradation effects may occur very rapidly after sampling and, with conventionally treated snap-frozen samples, the risk of further degradation returns when samples need to be thawed. Preliminary results indicate that Denator´s rapid heat inactivation technology stabilizes tissues instantly and this stability is maintained during downstream analyses. We are very optimistic that this new approach will bring us closer to the original biological state of the samples, facilitating data interpretation and opening the way to discover novel proteins and peptides that would previously have been lost."

Denator has recently set up several research collaborations to test its novel technology platform and obtain valuable user feedback during the critical product development stage. So far, results are very positive and CEO Olof Sköld is confident of being on the path to successful commercialization of the Denator technology.

Denator´s first commercial system for instant tissue stabilization will be launched at the HUPO meeting in Amsterdam in August, 2008.

About Denator
Established in 2004, Denator is headquartered at the Biotech Center in Göteborg, Sweden.